LCP (LifeCycle Pharma A/S) offers customized development programs to improve oral bioavailability of poorly soluble compounds
Oral Bioavailability is the keystone for the new and unique proprietary technology called MeltDose®.
MeltDose® technology is a one-step industrial process designed to enhance the oral bioavailability of poorly water soluble drugs. MeltDose® has been validated in numerous clinical studies, in partnerships with several leading pharmaceutical companies and by the FDA approval and launch of Fenoglide® on the US market.
Learn more about LCP, oral bioavailability and MeltDose®
5 Reasons to choose MeltDose®
1. Clinically proven
to improve bioavailability and/or reduce food effect
2. Commercially viable
with the first MeltDose® based product, Fenoglide® on the US market
3. Patent protected
4. Easily scalable
and requiring only conventional manufacturing equipment
5. Cost effective
as the cost of goods is comparable to conventional tablets